Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Drug discovery and development has long relied on expensive, time-consuming empirical trial and error. By shifting the discovery process onto computers, Isomorphic Labs wants to fundamentally change medicine from a process of discovery to one of precision engineering. Elad Gil sits down with Isomorphic’s president Max Jaderberg to discuss his vision for using predictive AI models to achieve experimental accuracy. Max details how the success of AlphaFold provided the first proof of concept that a deep learning model could generalize in the field of biology, and how an AI model’s compounding of learnings allows it to achieve generalizability with scale, thus greatly increasing the probability of success as well as speed in real world clinical trials. He also talks about evolving past the need for animal testing through in-silico models, Isomorphic’s focus on developing drug design engines that are agnostic of disease area, target class, and modality, why accurate molecule engineering unlocks the potential for multidrug cocktails that span complex biological pathways, and how he believes AI molecule optimization will improve both human lifespan and healthspan.
Sign up for new podcasts every week. Email feedback to show@no-priors.com
Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @MaxJaderberg | @IsomorphicLabs
Chapters:
00:00 – Trailer
00:45 – Max Jaderberg Introduction
01:24 – Isomorphic Origins
05:23 – Drug Discovery Stagnation
11:49 – Hiring at Isomorphic
14:35 – Bringing Drug Discovery Onto Computers
19:31 – Isomorphic’s Datasets
20:30 – Rethinking Endpoints
22:50 – External vs. Internal Dependences
23:57 – Automating Biologic Labs
26:22 – Internal Development vs. Partnerships
27:19 – Areas of Human Health Focus
29:21 – Multidrug Approaches
32:17 – Risk Appetite Variation
34:26 – Disease Treatment Outlook
35:42 – Human Longevity and Drug Development
39:16 – Conclusion
The Quest to ‘Solve All Diseases’ with AI: Isomorphic Labs’ Max Jaderberg
After pioneering reinforcement learning breakthroughs at DeepMind with Capture the Flag and AlphaStar, Max Jaderberg aims to revolutionize drug discovery with AI as Chief AI Officer of Isomorphic Labs, which was spun out of DeepMind. He discusses how AlphaFold 3's diffusion-based architecture enables unprecedented understanding of molecular interactions, and why we're approaching a "Move 37 moment" in AI-powered drug design where models will surpass human intuition. Max shares his vision for general AI models that can solve all diseases, and the importance of developing agents that can learn to search through the whole potential design space.
Hosted by Stephanie Zhan, Sequoia capital
Mentioned in this episode:
Playing Atari with Deep Reinforcement Learning: Seminal 2013 paper on Reinforcement Learning
Capture the Flag: 2019 DeepMind paper on the emergence of cooperative agents
AlphaStar: 2019 DeepMind paper on attaining grandmaster level in StarCraft II using multi-agent RL
AlphaFold Server: Web interface for AlphaFold 3 model for non-commercial academic use
Isomorphic Labs Discusses AI-Driven Drug Discovery and the Future of Medicine - Ep. 252
Max Jaderberg and Sergei Yakneen from Isomorphic Labs discuss how AI is enhancing drug discovery by treating biology as an information processing system. They share how advanced AI models like AlphaFold 3 are accelerating the pipeline and paving the way for a future of precision medicine.
How AI is saving billions of years of human research time | Max Jaderberg
Can AI compress the yearslong research time of a PhD into seconds? Research scientist Max Jaderberg explores how “AI analogs” simulate real-world lab work with staggering speed and scale, unlocking new insights on protein folding and drug discovery. Drawing on his experience working on Isomorphic Labs' and Google DeepMind's AlphaFold 3 — an AI model for predicting the structure of molecules — Jaderberg explains how this new technology frees up researchers' time and resources to better understand the real, messy world and tackle the next frontiers of science, medicine and more.
Hosted on Acast. See acast.com/privacy for more information.
Accelerating drug discovery with AI: Insights from Isomorphic Labs
In this episode of Gradient Dissent, Isomorphic Labs Chief AI Officer Max Jaderberg, and Chief Technology Officer Sergei Yakneen join our host Lukas Biewald to discuss the advancements in biotech and drug discovery being unlocked with machine learning.
With backgrounds in advanced AI research at DeepMind, Max and Sergei offer their unique insights into the challenges and successes of applying AI in a complex field like biotechnology. They share their journey at Isomorphic Labs, a company dedicated to revolutionizing drug discovery with AI. In this episode, they discuss the transformative impact of deep learning on the drug development process and Isomorphic Labs' strategy to innovate from molecular design to clinical trials.
You’ll come away with valuable insights into the challenges of applying AI in biotech, the role of AI in streamlining the drug discovery pipeline, and peer into the future of AI-driven solutions in healthcare.
Connect with Sergei Yakneen & Max Jaderberg:
https://www.linkedin.com/in/maxjaderberg/
https://www.linkedin.com/in/yakneensergei/
https://twitter.com/SergeiIakhnin
https://twitter.com/maxjaderberg
Follow Weights & Biases:
https://twitter.com/weights_biases
https://www.linkedin.com/company/wandb